| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
The specific molecular target of (+/-)-Lavandulyl acetate has not been extensively characterized. As a volatile terpenoid present in lavender oil, it may contribute to the biological activities of lavender essential oil, which include mild sedative, anxiolytic, and antimicrobial effects. However, its isolated target is not well-defined.
|
|---|---|
| ln Vitro |
Limited in vitro data is available for (+/-)-Lavandulyl acetate. As a component of lavender oil, it may exhibit weak antimicrobial activity and potentially modulate GABAergic signaling. However, the isolated compound has not been extensively studied for its in vitro biological effects, and most studies focus on the complex mixture of essential oils.
|
| ln Vivo |
In vivo data for the isolated compound is limited. As a constituent of lavender oil, which has been studied in animal models, potential activities include mild sedation (observed in inhalation studies) and reduced stress responses. However, the specific contribution of ( +/-)-Lavandulyl acetate to these effects remains unclear.
|
| Enzyme Assay |
The compound is primarily used as an analytical standard for essential oil characterization and natural product research, not for biological assays. Typical experimental procedures involve GC-MS analysis for identification and quantification, as well as GC-FID for purity assessment. These are chemical, not biological, assays.
|
| Cell Assay |
Cell-based assays are not standard for this compound. Researchers investigating its potential activity might use antimicrobial susceptibility tests (e.g., disc diffusion or broth microdilution) against bacterial or fungal strains. Typical protocols involve preparing serial dilutions of the compound and assessing growth inhibition.
|
| Animal Protocol |
Animal studies on the isolated (+/-)-Lavandulyl acetate are not common. Most studies focus on lavender essential oil mixtures. If conducted, typical protocols might involve inhalation exposure in rodent models (mice or rats) followed by behavioral assays (e.g., elevated plus maze, open field test) to assess anxiety-like behaviors.
|
| ADME/Pharmacokinetics |
No detailed pharmacokinetic data is available for this isolated compound. As a volatile monoterpene ester, it is likely rapidly absorbed via inhalation, metabolized by esterases to the corresponding alcohol and acetic acid, and eliminated. Detailed PK parameters have not been established in the literature.
|
| Toxicity/Toxicokinetics |
No direct toxicity data is available for this specific compound. As a component of lavender oil, which is generally regarded as safe when used appropriately, it is expected to have a low toxicity profile. However, isolated compound safety data is limited, and standard precautions should be taken.
|
| References | |
| Additional Infomation |
It has been reported that galangal (Alpinia galanga) contains lavender acetate, and relevant data is available. See also: Lavender oil (partial).
(+/-)-Lavandulyl acetate is a monoterpenoid ester for research use as an analytical standard. Its mechanism of action, if any, is not well-characterized. This compound has not entered clinical trials nor is it approved for therapeutic use. It is typically stored at -20degC with a purity of ≥95% and is intended for research and analytical applications only. |
| Molecular Formula |
C12H20O2
|
|---|---|
| Molecular Weight |
196.29
|
| Exact Mass |
196.146
|
| CAS # |
25905-14-0
|
| Related CAS # |
(-)-Lavandulyl acetate; 20777-39-3
|
| PubChem CID |
30247
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
0.907 g/mL at 20ºC(lit.)
|
| Boiling Point |
228.7ºC at 760 mmHg
|
| Flash Point |
103ºC
|
| Vapour Pressure |
0.0724mmHg at 25°C
|
| Index of Refraction |
n20/D 1.454
|
| LogP |
3.24
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
14
|
| Complexity |
235
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(=CCC(COC(=O)C)C(=C)C)C
|
| InChi Key |
HYNGAVZPWWXQIU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H20O2/c1-9(2)6-7-12(10(3)4)8-14-11(5)13/h6,12H,3,7-8H2,1-2,4-5H3
|
| Chemical Name |
(5-methyl-2-prop-1-en-2-ylhex-4-enyl) acetate
|
| Synonyms |
(±)-Lavandulyl acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.0945 mL | 25.4725 mL | 50.9450 mL | |
| 5 mM | 1.0189 mL | 5.0945 mL | 10.1890 mL | |
| 10 mM | 0.5095 mL | 2.5473 mL | 5.0945 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
